Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates
UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell ...
Checkpoint Therapeutics, Inc: Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates
Checkpoint Therapeutics, Inc. ("Checkpoint") (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology company, today announced financial ...
Pharmabiz23h
Sichuan Kelun-Biotech’s radionuclide-drug conjugate SKB107 receives China NMPA approval to treat bone metastases in solid tumours
Biotech’s radionuclide-drug conjugate SKB107 receives China NMPA approval to treat bone metastases in solid tumours: Chengdu, China Friday, March 28, 2025, 15:00 H ...
C&EN13h
12 drug candidates debut in San Diego
BMS-986458 features three stereocenters, one of which epimerizes easily, Mortensen said. The drug candidate, which would be ...
JD Supra16h
FDA Approves Fresenius’s Denosumab Biosimilars
On March 26, 2025, the FDA approved Fresenius Kabi’s denosumab biosimilars, CONEXXENCE® (denosumab-bnht) and BOMYNTRA® (denosumab-bnht), ...
Indiatimes14h
Nifty Pharma
Tracks the performance of pharmaceutical companies in India, comprising leading pharmaceutical stocks listed on the National Stock Exchange (NSE), reflecting trends in the pharmaceutical sector.
Indiatimes14h
Piramal Pharma Share Price
Rights Aug 02, 2023 Aug 02, 2023 Feb 08, 2023 Rights ratio: 5 share for every 46 held at a price of Rs 81.0 ...